Are you interested in a new treatment for Alzheimer's disease?

A clinical trial to assess the safety and effectiveness of a new treatment for Alzheimer’s disease (NAVIGATE AD)

Although the cause of Alzheimer’s disease is not yet clearly understood, it is believed that proteins in the brain, called beta-amyloid, are responsible. LY3202626 blocks a protein in the body called BACE1 that is responsible for the build-up of beta-amyloid. This study will look at whether the action of LY3202626 slows the progression of Alzheimer’s disease.

This study will look to answer the following research questions(s):

  • The safety of LY3202626 and any side effects you might have when you take it.
  • Whether LY3202626 can help patients with Alzheimer’s disease.
  • How much LY3202626 should be given to patients.

Anticipated date that enrolment will close: December 2018

Who can take part

  • People aged between 55 and 85 years
  • Diagnosis of Alzheimer's Disease (MMSE 20-26)
  • People living in the community
  • Must have a study partner who is able to attend all visits with participant

What is involved for you

  • Four visits in first month, then monthly visits for 1 year
  • MRI and PET (x2) scans at beginning and end of study
  • Numerous cognitive tests (beginning, middle and end of study)
check
Non-Drug
Phase 1
Phase 2
Phase 3
Phase 4

For more information

Quote reference number
2016.121
Lucy Vivash
03 9342 7500